AKYA: Akoya Biosciences Inc Price to Sales

Symbol and logo of brand Akoya (AKYA)

The potential of Akoya Biosciences (AKYA) relies on the expansion of its instrument network and the recognition of its tissue analysis methods in oncology. Examining the current P/S multiple on GURU.Markets, we see that the parameter reaches 0.80. However, high costs and the slow adoption of innovations in clinics constrain growth, while the geopolitical stability of biomedicine minimizes external threats to the business.

AKYA (Akoya) P/S Multiple history from 07/04/2022 to 07/19/2025

Analytical breakdowns for Akoya Biosciences (AKYA)

- market price and analyst price targets:
Stock Quotes akoyabio.com|AKYA - Analyst Consensus Forecast
- market capitalization information:
Market Value Akoya|AKYA - Enterprise Value
- shareholders' equity book value data:
Equity per Share Akoya Biosciences|AKYA - Book Capitalization|Market Capitalization to Book Value akoyabio.com|AKYA - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Akoya Biosciences|AKYA - Long-Term Debt to Capital|Short-Term Debt to Capital akoyabio.com|AKYA - Company Debts|Debt to Book Capitalization Ratio Akoya|AKYA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Akoya Biosciences|Immediate Liquidity akoyabio.com
- net income and valuation multiples indicators:
AKYA - Company Net Income|Projected Net Profit Akoya Biosciences|AKYA - Price to Earnings Ratio|Forward P/E Multiple akoyabio.com|AKYA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Akoya|AKYA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Akoya Biosciences|AKYA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months akoyabio.com|AKYA - Earnings growth in current year|Expected net earnings per share growth next year Akoya Biosciences
- issuer revenue and sales details:
AKYA - Company Revenue|Company Revenue Forecast akoyabio.com|AKYA - Market Cap to Revenue|Price to Expected Revenue Ratio Akoya
Fundamental company analysis:Akoya Biosciences Inc AKYA
Original product of Akoya Biosciences

Investors use this ratio to determine whether an asset is overbought relative to its actual sales by assessing the market value of one dollar of revenue. Analyzing the market capitalization-to-revenue ratio reveals that the high valuation of Akoya Biosciences (AKYA) is supported by the retention of unique bioanalysis specialists and software integrators, which minimizes the business's technological risks.

Who Akoya Biosciences competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio MaxCyte, Inc.|RPID - Price-to-Revenue Multiple|Market Cap to Revenue SEER (Seer)|P/S Multiple Hyperfine Inc (HYPR)|P/S Multiple FONR (FONAR Corp)|Price-to-Revenue Coefficient Daxor Corp (DXR)|MDAI - Price-to-Revenue Ratio|Price-to-Sales Ratio VIVS|Aclarion, Inc. (ACON) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO